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Background: Immunophenotyping is a valuable ancillary technique for the differential diagnosis between
myelodysplastic syndromes (MDS) with low bone marrow (BM) blast counts and a normal karyotype, and reactive
peripheral (PB) cytopenias. Our aim was to search for the most important variables for this purpose. We also
analyzed the age variation of BM B-cell precursors (BCP) and its differences in reactive and clonal cytopenias.
Methods: Immunophenotypic analyzes were performed in BM of 54 patients with MDS (76% with BM blasts <5%)
and 35 cases of reactive cytopenias. Healthy allogeneic BM transplantation donors (n = 41) were used as controls.
We used a four-color panel of antibodies analyzing 9 granulocytic, 8 monocytic and 6 CD34+ cell features.
Results: Asynchronous shift to the left in maturing granulocytes and increase in CD16+ monocytes were also found
in reactive PB cytopenias, but the most important aberrancies in MDS were seen in myeloid CD34+ cells. Decrease
in BCP, that is a hallmark of MDS, could also be found in reactive cytopenias, especially in patients >55 years. %
BM BCP could be calculated by the formula: (−7.97 × log age) + (4.24 × log % CD34+ cells) – (0.22 x nr. alterations
CD34+ cells) + 0.577. Corrected R2 = 0.467.
Conclusion: Analysis of myelomonocytic precursors and CD34+ cells was satisfactory for the differential diagnosis
between reactive PB cytopenias and MDS. The most specific alterations were found in CD34+ cells. Comparison of
the values obtained with those of normal age-matched controls is recommended.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1975931809154663
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In the last years, numerous studies have confirmed the
utility of multiparametric flow cytometry (FCM) in the
diagnosis of myelodysplastic syndromes, especially in
cases with a normal karyotype, and its differential diag-
nosis with peripheral cytopenias of non-clonal origin
[1-10]. FCM of BM hemopoietic precursors has been* Correspondence: ilmetze@unicamp.br
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unless otherwise stated.focused mainly on myelomonocytic precursors and
CD34+ progenitors. There is no single specific abnor-
mality, but the presence of three or more aberrancies
may strongly support the diagnosis of MDS [1,2].
Several kinds of phenotypic abnormalities have been
described in MDS such as a low SSC in granulocytic
precursors, loss of antigen expression, asynchronous
maturation or maturation block, aberrant cross-lineage
co-expressions, quantitative and qualitative abnormalities
of CD34+ cells, along with the decrease of precursor B
cells (BCP) [9,11-21]. Many phenotypic abnormalities
found in CD34+ cells have been associated with diseaseral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinical and hematological features of MDS patients
N° of patients 54
Sex (male/female) 34/20
Age, median years (range) 69 (15–84)
WHO classification, n° (%) of the patients
RA 7 (13)
RCMD 24 (45)
RCMD-RS 11 (20)
RAEB-1 6 (11)
RAEB-2 6 (11)
IPSS-R risk group of the patients
Very Low 5
Low 17
Intermediate 16
High 10
Very High 3
IPSS risk group of the patients
Low 15
Intermediate-1 25
Intermediate-2 9
High 2
WPSS of the patients
Very low 3
Low 12
Intermediate 22
High 12
Very High 2
WHO, World Health Organization; RA, refractory anemia; RCMD, refractory
cytopenia with multilineage dysplasia; RAEB, refractory anemia with excess
blasts; IPSS International Prognostic Scoring System; WPSS, WHO classification-
based prognostic scoring system; ANC, absolute neutrophil count.
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the patients [5,8,10,15,17,19,20,22-31].
According to the European Leukemia Net Working
Group (ELN) standardization [3,6,31], BM immunophe-
notyping in MDS should at least focus on the matur-
ation of myelo-monocytic precursors as well as the
enumeration of hemopoietic progenitors and BCP. So,
a minimal panel should be designed to detect all these
abnormalities [3,5,8,22,31]. Furthermore, comparison
with the normal pattern of antigen expression of each
lineage and maturation step should be performed.
Besides, several scores based on phenotypic findings
have been described to support the differential diagno-
sis between MDS and reactive PB cytopenias, but there
is no general consensus indicating the best one for
application in daily routine [5,8,10,15,17,23,25-31].
In our previous studies [10,19,23], we have analyzed
the utility of a four-color panel that was able to detect
several phenotypic abnormalities in the myelomonocy-
tic series and CD34+ cells. We have also found that
maturation abnormalities of myelomonocytic precur-
sors are similarly present in all WHO types of MDS,
while those detected in CD34+ cells are the most im-
portant to predict a shorter survival of the patients
[19,20]. Recently, comparing the prognostic value of
IPSS, IPSS-R and WPSS with those obtained by flow
cytometry, we found that CD34+/CD13+ cells and total
number of phenotypic alterations found in the myelo-
monocytic series and CD34+ cells were additional inde-
pendent prognostic factors to the clinical scores [23].
Here, our aim was to examine which abnormalities de-
tected by our panel were more important for the differen-
tial diagnosis between reactive PB cytopenias and cases of
MDS with a normal karyotype. As the number of BM
B-cell precursors is age-dependent, we also examined the
impact of this variation in the utility of this feature in the
differential diagnosis.Methods
Patients and samples
Since December of 2009, immunophenotyping was
included in the diagnostic work-up of peripheral cyto-
penias in our Institution together with PB counts, BM
cytology and karyotyping. The WHO criteria were used
for the diagnosis of MDS and exclusion of deficiency
anemias, viral infections, auto-imune diseases and renal
or hepatic insufficiency was made [1,2]. During the
period of the study (December 2009 – February 2013),
we could confirm the diagnosis of MDS in 56 cases
while in 35 cases the final diagnosis of reactive cytope-
nias was made (Table 1). Twenty five patients were
excluded because of lack of complete clinical data or
uncertain diagnosis.The classification of the MDS cases was made according
to the WHO criteria and risk category according to IPSS,
IPSS-R [32] and WPSS (using hemoglobin values instead
of “transfusion dependency”) [33] was assessed.
Cytogenetic analysis of BM was performed after 24 hours
of culture according to standard methods. In each case, at
least 20 mitoses were analyzed and the karyotypes were
reported according to the International System for Human
Cytogenetic Nomenclature [34].
Normal BM samples were obtained from 41 healthy
donors for allogeneic bone marrow transplantation (age:
15–69 years) in order to standardize a normal immunophe-
notypic profile for our laboratory. All samples were collected
during the period between July 2009 and January 2013.
All BM samples were obtained after informed consent
was given by each person, according to the recom-
mendations of the local Ethics Committee (proc. Nr.
0652.0.146.000-08).
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Immunophenotyping was performed as previously
described [10,19]. Briefly, the EDTA-anticoagulated BM
sample (5-7 × 106 cells in 100 μl per test) was processed
using a standardized direct lyse-and-wash technique
within 24 hours after bone marrow aspiration [3]. Quality
control, calibration and compensation with FACS Comp
were performed daily in our equipment.
Antigenic expression was studied using four-color com-
binations of monoclonal antibodies (MoAbs) conjugated
with fluorescein isothiocyanate (FITC), phycoerythrin
(PE), peridin clorophyll protein (PerCP) and allophyico-
cyanin (APC) fluorocromes. The following combinations
were used to study the myelomonocytic maturation and
progenitor cell populations: HLA-DR/CD14/CD45/
CD33; CD16/CD11b/CD45/CD13; CD13/CD34/CD45/
CD117; CD10/CD19/CD45/CD34; CD7/CD56/CD45/
CD34. The specificity and source of each reagent have
already been described in detail [23]. Immediately after
staining, samples were acquired in a FACS Calibur flow
cytometer (Becton Dickinson – BD Biosciences) using
the CellQuest software (BD Biosciences). Instrument
quality control, calibration using FacsComp™ (BD) software
and spectral compensation were performed daily. Informa-
tion about at least 100,000 nucleated BM cells was ac-
quired for each sample. Data analysis was made using
Infinicyt software (Cytognos). The strategies of analysis
were standardized as previously described [10,19,23]. These
variables also were assessed in normal BM.Table 2 Comparison of flow cytometric features among norm
Normal values
n = 41
Reactive cytopen
n = 35
Granulocytic series
SSC 521 (396–658) 534 (340–628)
CD45 MFI 138-577 265 (107–683)
Asynchronous shift to
the left
7 (21%)
Monocytic series
SSC 253 (196–399) 237 (149–390)
% monocytes 0.8-3.6 3.0 (0.7 - 8.8)
% CD16+ monocytes <0.48 0.3 (0.1 - 3.4)
Cells in the blast gate
BM % blasts (cytology) 1.0 (0.5 - 4.0)
% CD34+ cells <1.59 0.6 (0.02-2.1)
% B cell precursors/total cells >0.05 (0.04-0.53) 0.06 (0–0.7)
%CD34+/CD13+/CD117+ <0.62 0.3 (0.01-0.8)
% CD34+/CD7+ <0.08 0.05 (0–0.09)
% CD34+/CD56+ <0.05 0.01 (0–0.09)
Total abnormalities 0 (0–2) 2 (0–5)The analysis of the myelomonocytic series was made
as previously described [23] according to ELN standar
dization [3,27,31]. Briefly, maturation pattern of neutro-
phils was analyzed by their expression of CD13, CD16,
CD11b, CD33 and HLA-DR. The side-scatter (SSC) of
the granulocytic population and the antigen expressions
were considered abnormal if the values of the mean
fluorescence intensity (MFI) were above or below the
benchmark values obtained for the normal cases (Table 2).
Monocytes were analyzed by their expression of HLA-DR,
CD64 and CD14. The combination CD16/CD11b/CD45/
CD13 was used to quantify the CD16+ monocytes. The
aberrant expression of CD34, CD7 and CD19 was
investigated in each population considering abnormal
when at least 10% of the cells expressed these antigens.
For expression of CD56 in the myelomonocytic cell line,
only values of >20% for granulocytes and >50% for mono-
cytes were considered abnormal.
CD34+ cells were separated in the SSC/CD34 dot
plot [10,19] (Figure 1) and their co-expression of
CD19, CD10, CD13, CD117, CD7 and CD56 was ex-
amined. The B-cell precursors (CD34+/CD19+/CD10+)
were measured as percentage of the total nucleated
cells.
All immunophenotypic features were compared with
the values found in normal BM. We computed the total
number of granulocytic and monocytic abnormalities, as
well as those of CD34+ cells. We also computed the sum
of all abnormalities found.al, non-clonal cytopenias and MDS
ias MDS <5% BM blasts
n = 42
MDS >5% BM blasts
n = 12
p
394 (236–619) 462 (319–648) <0.0001
216 (34–770) 270 (89–551) 0.02
11 (26%) 6 (46%) 0.12
233 (66–399) 203 (184–322) 0.01
3.7 (0.2 - 18) 3.3 (0.1 - 21) 0.22
0.4 (0.02 - 10) 0.9 (0.05 - 4) 0.003
1.0 (0.5 - 5) 12 (7.7 - 18)
1.0 (0.02- 5.1) 3.6 (0.2 - 28) <0.0001
0.06 (0–0.7) 0.01 (0.01 - 0.14) <0.0001
0.5 (0.01-4.2) 1.4 (0–24.1) 0.001
0.04 (0–0.7) 0.13 (0.04-26) <0.0001
0.03 (0–1.9) 0.13 (0.02-27) <0.0001
7 (3–13) 9 (6–16) <0.0001
Figure 1 CD34+ subsets in normal, reactive cases (idiopathic thrombocytopenia) and MDS (RCMD) analyzed in the CD13/CD34/CD45/CD117
combination. Red: CD34+/CD117−/CD13− cells that represent the immature precursors and B-cell precursors. Cyan: CD34+/CD117−−/CD13+ cells
characterizing the immature myeloid precursors. Green: CD34+/CD117+/CD13−− representing early myeloblasts and early pro-eritroblasts. Yellow:
CD34+/CD117+/CD13+ cells (myeloblasts). Purple: CD34−−/CD117+/CD13+ cells (promyelocytes). Blue: CD34−/CD117+/CD13−− cells = proeritroblasts.
The maturation patterns can be analyzed in the CD34/CD117 combination (A), CD13/CD117 combination (B) and CD13/CD34 combination (C).
The myeloblasts (yellow) are increased in MDS.
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The mean values and standard deviation were obtained
for all variables analyzed. The difference between groups
was assessed by analysis of variance. The normal distri-
bution of the features of normal hemopoiesis was exam-
ined by the Kolmogorov-Smirnov test, and those with a
non-normal distribution were submitted to a log trans-
formation. The relation of B-cell precursors with age
and among the groups studied was examined using the
Spearman rank order correlation and multiple regres-
sions. Values were considered significant when p < 0.05.The Winstat and SPSS.15 softwares were used for the
calculations.
Results
Patients’ characteristics
Concerning patients with MDS, the majority were RCMD
(Table 1). In 5 cases no mitoses were available for karyo-
typing. As some of the patients’ groups in IPSS-R and
WPSS classification were rather small, we grouped the
cases with <5% BM blast (low risk) and MDS with > 5%
BM blast (high risk) for analysis. A major part of the
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scores analyzed and had BM blasts <5%.
The cases with non-clonal cytopenias included defi-
ciency anemias (n = 11), drug-induced cytopenias (n = 6),
aplastic anemia (n = 3), idiopathic thrombocytopenic
purpura (n = 4), auto-immune diseases (n = 4), thyroid
dysfunction (n = 3), and infection-associated leucopenia
(n = 4). There were 15 men and 20 women with a
median age of 60 years (14–86).
The normal values were established by the analysis
of 41 normal donors of allogeneic bone marrow
transplantation with a median age 32 years (15–69);
25 males and 16 females. All features examined ex-
cept for MFI for SSC in the granulocytic precursors
and total B-cell precursors presented a normal distri-
bution. So we used the mean values obtained ± 2
standard deviations except for MFI SSC of myelomo-
nocytic cell lines and percentage of total B-cell
precursors. For these two features we used the 5%
and 95% percentiles, due to the large variation
observed in the normal controls.Table 3 Frequencies of several abnormalities detected in non
Alterations Reactive cytopenias
(n = 35)
M
<5
Granulocytic series
Abnormal granularity 0 17
Abnormal decrease in CD45 expression 3 9
Abnormal pattern in CD13/CD16 2 23
Abnormal pattern in CD33/HLA-DR 7 26
Expression of CD56 0 9
Aberrant expression of CD34 1 7
Aberrant expression of CD7 1 2
Aberrant expression of CD19 0 4
Asynchronous shift to the left 7 11
Monocytes series
Abnormal granularity 7 12
Abnormal % Monocytes 11 27
Increase of % Monocytes CD16+ 8 19
Abnormal pattern in CD33/HLA-DR 5 21
Expression of CD56 6 14
Aberrant expression of CD34 1 17
Aberrant expression of CD7 1 9
Aberrant expression of CD19 1 5
Cells in the blast gate
Increase of % CD34+ cells 1 11
Increase of % CD34+/CD13+/CD117+ 4 18
Anomalous expression of CD7 0 9
Anomalous expression of CD56 2 15Immunophenotypic analysis
Reactive cytopenias
Flow cytometric data of non-clonal cytopenias are shown
in Table 2. There was no abnormality concerning SSC of
granulocytes and monocytes. Shift to the left, with asyn-
chrony of antigen expression was found in 7 cases
(Table 3). In two cases, abnormal maturation pattern in
CD13 or CD16 was observed in maturing granulocytes.
There was one case with an autoimmune disorder pre-
senting expression of CD34 in maturing granulocytes
without any other abnormality, and one with hepatitis C
at diagnosis presenting expression of CD7 in maturing
granulocytes. In 9 cases (26%), increased percentages of
monocytes were found.
There was an increase of CD16+ monocytes in 8 cases
of reactive cytopenias. A statistical difference was found
among normal, reactive cytopenias and MDS. CD56 was
expressed in monocytes in 2 cases, CD7 and CD19 were
expressed in one case each (cases with deficiency anemia).
The percentage of total CD34+ cells and %CD34+/
CD117+/CD13+ cells (myeloid blasts) were increased-clonal cytopenias and MDS
DS low risk
%BM blast (n = 42)
MDS high risk
>5% BM blast (n = 12)
p value for X2
3 0.001
1 0.245
8 0.0001
9 0.0001
1 0.018
3 0.06
1 0.776
0 0.101
6 0,227
0 0.10
9 0.04
8 0.015
2 0.01
3 0.20
6 <0.0001
5 0.008
2 0.278
10 <0.0001
9 0.001
8 <0.0001
9 <0.0001
Figure 2 Distribution of bone marrow B-cell precursors according to
the age of the patients. A- Variation observed in normal controls
and reactive peripheral cytopenias. Decrease is more pronounced in
subjects > 55 years old. B- B-cell precursors in MDS. The number
of cells is very low, and frequently absent in patients >55 years old,
but it can be present in younger persons.
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shift to the left in the granulopoiesis. CD56 was expressed
in 2 cases (0.06% and 0.09% of the cells). B-cell precursors
were below the normal value in 14 cases (41%). All these
alterations resulted in an increased number of total
abnormalities.
Abnormalities observed in MDS
The abnormalities found in MDS are also shown in
Tables 2 and 3. Most of the aberrancies studied were more
common in MDS than in reactive cases. Concerning
CD34+ cells, they were increased in 26% of the cases of
MDS with BM blast count <5% in cytology and in 83%
of the cases with RAEB. The same was true for the cells
with the phenoptype CD34+/CD13+/CD117+ (Table 3).
Abnormal co-expressions were rare in reactive cytopenias
and common in MDS (Table 3).
Relation between B-cell precursors and age
Considering all the subjects studied, the median age was
55 years. Within the groups, normal subjects had a median
age of 32 years (range: 15–69); reactive cytopenias: 60 years
(range: 14–86) and MDS: 69 years (range: 15–84).
In the Spearman’s test, there was a negative correlation
between age and BCP in all three groups: r = − 0.328;
p 0.023 for healthy donors; r = − 0.321; p = 0.032 for react-
ive cytopenias (Figure 2A) and r = − 0.412; p = 0.002 for
MDS cases (Figure 2B). These cells were absent in none of
the normal donors, in 8/35 cases of reactive cytopenias
and in 33/54 cases of MDS.
Among the subjects with age <55 years, mean B-cell pre-
cursors were 0.18%, 0.14% and 0.17% in normal controls,
reactive cytopenias and MDS cases respectively, which was
not significantly different. Among subjects >55 years old,
mean values were 0.28%, 0.075% and 0.015% respectively.
These values were significantly different (p < 0.005).
In the multiple regressions considering age, total %
CD34+ cells, BCP and number of alterations in CD34+
cells, the relation could be described in non-clonal sub-
jects (normals and reactive cytopenias) by the equation:
% BCP ¼ −7:3  log ageð Þ þ 8:2  log % CD34þcellsð Þ þ 0:46
corrected R2 ¼ 0:265
For the MDS cases the equation was:
%BCP ¼ −7:97  log ageð Þ þ 4:24  log% CD34þcellsð Þ
– 0:22  nr:alterations CD34þcellsð Þ þ 0:577
corrected R2 ¼ 0:467
Discussion
Several immunophenotypic abnormalities have been
described in MDS. According to the WHO 2008 rec-
ommendations [1], the finding of three or more abnor-
malities is considered highly suggestive of MDS. Thus,immunophenotyping has been considered a useful ad-
juvant method for the diagnosis of MDS in cases with
low BM blast counts and a normal karyotype [2]. This
technique is also widely used for the diagnosis and as-
sessment of minimal residual disease in several other
hematological neoplasms [35,36].
Knowledge of normal antigen expression of the several
hemopoietic cells and its changes during normal cell mat-
uration is essential to assess abnormalities and to define
leukemia-associated immunophenotypes (LAIPs) [3,8]. It is
also advisable for each laboratory to establish their own
reference normal values for each panel of monoclonal anti-
bodies used. In healthy individuals, normal maturation of
BM precursors is genetically tightly controlled, leading to
predictable patterns of antigen expression at different
stages of cell maturation. Neoplastic cells are characterized
by a deviation of this pattern, as well as by the presence of
aberrant cross-lineage antigen expressions [4,5,8,12,37].
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a rather small four-color panel of monoclonal antibodies
analyzing the myelomonocytic lineage and the subsets of
CD34+ cells was suitable to confirm the diagnosis of
MDS and allowed us to detect independent prognostic
features [23]. Among the phenotypic abnormalities
found, those concerning CD34+ cells were the most im-
portant to predict a shorter survival of the patients. At
last we substituted the combination for analysis of den-
dritic cells and basophils for a combination (CD7/CD56/
CD45/CD34) to assess the most frequent leukemia-
associated phenotypes. Both minor populations are al-
tered in MDS, but are less important for the differential
diagnosis of clonal and non-clonal cytopenias.
In the present work, our aim was to examine which
variables detected by our panel were more important to
discriminate between reactive PB cytopenias and MDS, es-
pecially in those cases with few BM blasts and a normal
karyotype. Concerning the variables analyzed, our reactive
cases never presented a decreased SSC or a maturation
block in the myeloid series. Shift to the left was seen in 7
cases and abnormal expression of CD13 was seen in 2 cases.
This is in keeping with the fact that, although variation in
antigen expression may occur in reactive cytopenias, the
rupture of the normal pattern of maturation should never
be seen, as this is indicative of a clonal disorder.
Concerning monocytes, increase in number and expres-
sion of CD16 and CD56 that are indicative of cell activa-
tion, were observed, although this was more frequent in
MDS, as it also has been observed by others [31].
The main immunophenotypic features distinguishing
low-risk MDS from reactive cytopenias were the increase
of CD34+ cells, especially in the presence of normal blast
counts in cytology, increase in CD34+/CD117+/CD13+
cells, decrease in B-cell precursors, and aberrant co-
expressions in CD34+ cells (CD7 or CD56 or decrease in
CD13). The presence of anomalous expression of CD7 in
CD34+ cells was more frequent in high-risk MDS and
might reflect progression to leukemia.
The total number of phenotypic abnormalities was
also significantly higher in clonal disorders, confirming
previous results of our group and others [12,19,24-28].
Overall, in patients with reactive cytopenias, if pheno-
typic abnormalities are found, a close follow-up of the
patient should be made in order to detect a possible evo-
lution to an overt MDS.
The decrease of B-cell precursors has been considered
a hallmark of MDS [6,9,13,21,31], even in children. This
variable has also been included in phenotypic scores for
diagnosis of MDS, such as that proposed by Ogata and
included in the guidelines of ELN [31]. B-cell precursors
may be assessed as CD34+ cells with a low SSC or by their
phenotype, which is the way to obtain more reliable results.
We also assessed these cells as their percentage among allcells examined and not as percentage of all CD34+ cells, as
has been recommended by several authors [11,24,30,37]. In
MDS it is expected that myeloid progenitors may be in-
creased, provoking a false relative decrease of B-lymphoid
precursors. So, the best way to evaluate their number
would be to use their percentage among all cells.
On the other hand, it is well known that the number
of BM B-cell precursors have a strong variation with age
[38]. This was also the case in the present study. We
could show that in a multiple regression, their number
was dependent of age and the total number of CD34+
cells. In MDS, also the total alterations observed in
CD34+ progenitors entered the equation.
In subjects with age below 55 years the difference in
number of BCP was not so pronounced, but in older
patients, their number was below normal in reactive
cytopenias and this was more pronounced in MDS. This
is in keeping with an ageing process of the immune
system, which is highly variable with age and amount of
exposure to antigen stimulation. The pathophysiology of
the decrease of B-cell precursors observed in MDS is
not well understood. But, it has been described that
these cells may also present abnormalities in antigen
expression in MDS [21] that are more pronounced in
cases with a higher number of BM blasts. This could be
due to a more pronounced dysfunction of hemopoietic
progenitors that loose their capacity to produce the
B-cell line.Conclusion
In conclusion, an antibody panel focused on the analysis
of the myelomonocytic cell line and CD34+ cells was sat-
isfactory for the differential diagnosis between reactive
PB cytopenias and MDS with low BM blast counts and a
normal karyotype. The most specific alterations were
found in CD34+ cells. The number of BCP was more
discriminative in older patients. For young patients it is
necessary to compare their number with normal age-
matched subjects.Abbreviations
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